That’s how I feel, ER. Mixed for sure but he did settle w cydy a few years ago, both claimed (had to) to bury the hatchet, RP got his shares back and both parties said they would work together on LL for the common good. Nothing for a while after that then RP surfaces to head LL oncology efforts in late 2024.

mTNBC starts to gain momentum, CRC is building steam, glioblastoma doesn’t show the results we had hoped for but repeat studies occur due to previously unpublished data by RP and so we wait also for those results. Keytruda and Trodelvy are also being considered with LL. Chemo promotes CCR5 expression yet 100%RO with LL helps not only repolarize M2s to M1s, it hampers metastases, decreases angiogenesis and allows mitochondrial repair. Ohm has filled us in on this and the rest.

Mixed feelings initially and while there are still some there, I think those of us who were around before 2020 have wondered, especially after 13D, if the hatchet had beed buried.

In addition to all I mentioned above, RP now has at least 5 years of Hungarian funding, new prestigious appointments, and is off to München in May to walk through the English Gardens along the Isar, and ponder a very bright future for us, in between ESMO sessions.

Someone please pass the popcorn. This is getting good.